Category

NAA questioning consumer goods and pharma organizations regarding GST prices

NAA questioning consumer goods and pharma organizations regarding GST prices

The National Anti-Profiteering Authority (NAA) are questioning around 150 consumer goods and pharma companies regarding their stocks with the distributors and stockists on June 30,2017 were s...

Indian Pharma to enter Profitable Chinese market soon

Indian Pharma to enter Profitable Chinese market soon

Finally, Indian pharma companies are finding a way to enter the world’s second largest pharmaceutical market which is attractive and profitable market of China. Usually it takes 5 years...

Sun Pharma to be the top struggler Pharma stock down

Sun Pharma to be the top struggler Pharma stock down

On Tuesday’s trading session the pharma stocks were down during the last hour, the Biocon was down 1.52 percent, Sun Pharmaceutical industries (down 1.33 percent),Divi’s L...

Training programme for the Pharmaceutical industries by China

Training programme for the Pharmaceutical industries by China

China which is the second largest drug market after US has agreed to provide a specific training programme for the domestic pharmaceutical industries to understand their regulatory system, th...

Halol plant clearance improved the pharma stock

Halol plant clearance improved the pharma stock

As the Sun pharma’s Halol plant got clearance from the US FDA brought the pharma stocks into lime light on Wednesday giving a big relax to the pharma stocks. The Nifty pharma indexed cl...

FDAs clearance to Sun Pharma s Gujrat plant India

FDAs clearance to Sun Pharma s Gujrat plant India

Sun Pharma’s Halol plant in Gujarat, India has finally got some relief from the US FDA after receiving satisfactory report from the Food and drug administration. Since 2014 the plant fa...

Global quality standard to be followed by Pharma Industry Oppi

Global quality standard to be followed by Pharma Industry Oppi

The Organization of Pharmaceutical Producers of India-Oppi, which represents the research-based pharmaceutical companies in India and involved with the government and other stakeholders to ge...

Future growth of Lupin with multifaceted generics biosimilar and speciality medicines

Future growth of Lupin with multifaceted generics biosimilar and speciality medicines

Drug firm Lupin is now focusing on generics, biosimilar and speciality medicines to be the growth driver for going forward as per the investor presentation by the company. Although the compan...

Previous Page Next Page
1 2 3 4 5 6 7 8 9 10